Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)

Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. Despite advances in modern therapy, patients with relapsed or metastatic disease have a very poor clinical prognosis. Fibroblast Growth Factor Receptor 4 (FGFR4) is a cell surface tyrosine kinase receptor that is involved in no...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Samuel Q., Cheuk, Adam T., Shern, Jack F., Song, Young K., Hurd, Laura, Liao, Hongling, Wei, Jun S., Khan, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790700/
https://www.ncbi.nlm.nih.gov/pubmed/24124571
http://dx.doi.org/10.1371/journal.pone.0076551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790700/
https://www.ncbi.nlm.nih.gov/pubmed/24124571
http://dx.doi.org/10.1371/journal.pone.0076551

Ejemplares similares